Findings

What do systematic reviews say?

90 questions · 91 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 4.4%GRADE not reported 59 · 64.8%Very low 25 · 27.5%Low 3 · 3.3%Moderate 0 · 0%High 0 · 0%

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Adverse effects: Clinically important general adverse effect (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Leaving the study early · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 1.95 [0.36, 10.58]
1 study · 46 participants
Very low

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Adverse effects: Clinically important general adverse effect (no data) · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes adverse effects: Clinically important general adverse effect compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 1.34 [0.82, 2.18]
1 study · 57 participants
Very low

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

Leaving the study early · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes leaving the study early: Any reason compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 2.15 [0.49, 9.41]
4 studies · 140 participants
Very low

Zuclopenthixol dihydrochloride (Cis Z isomer) vs Zuclopenthixol (Cis Z/Trans E isomer)

General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs placebo

Leaving the study early · patients with schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).

2 findings from 2 reviews · compare the 2 reviews

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 0.29 [0.01, 6.6]
2 studies · 100 participants
Very low
Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
RR 0.93 [0.06, 13.54]
1 study · 29 participants
Very low

Zuclopenthixol dihydrochloride vs placebo

Global state: Average endpoint global state score (clinically improved) (no data) · patients with schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

Mental state · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 221 participants
Low

Zuclopenthixol dihydrochloride vs chlorpromazine

Leaving the study early · schizophrenia

Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 0.54 [0.36, 0.81]
6 studies · 766 participants
Low